Stockscreener 앱 받기
11.64
1.04%
0.12
시간 외 거래:
11.64
전일 마감가:
$11.52
열려 있는:
$11.53
하루 거래량:
871.25K
Relative Volume:
0.52
시가총액:
$3.66B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-17.11
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+2.37%
1개월 성능:
+19.75%
6개월 성능:
+58.37%
1년 성능:
+29.33%
1일 변동 폭
$11.44
$11.71
1주일 범위
$11.38
$12.12
52주 변동 폭
$6.685
$12.12
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.64 | 3.62B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Multi asset correlation models including Amneal Pharmaceuticals Inc.Jobs Report & Technical Pattern Based Buy Signals - newser.com
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones indexMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Why The Narrative Around Amneal Is Shifting Amid Analyst Revisions and Recent FDA Approvals - Yahoo Finance UK
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneMarket Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedPrice Action & Growth Focused Investment Plans - newser.com
Amneal gets FDA nod for Iohexol Injection - MSN
Amneal Pharmaceuticals (AMRX): Valuation Perspective After FDA Greenlight for First Generic Omnipaque and Raised Guidance - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock By Investing.com - Investing.com Australia
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Is Amneal Pharmaceuticals Inc. stock ready for a breakout2025 Top Gainers & Community Verified Trade Signals - newser.com
Amneal gets FDA nod for Iohexol Injection (AMRX:NASDAQ) - Seeking Alpha
Amneal Receives U.S. FDA Approval for Iohexol Injection - The Manila Times
Amneal (NASDAQ: AMRX) expects to launch first generic Omnipaque iohexol in Q1 2026 - Stock Titan
Published on: 2025-11-13 05:47:52 - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playPortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Real time breakdown of Amneal Pharmaceuticals Inc. stock performanceEarnings Overview Report & Weekly High Potential Stock Alerts - newser.com
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD By Investing.com - Investing.com Philippines
Is Amneal Pharmaceuticals Inc. stock resilient to inflationTrade Volume Summary & Long-Term Growth Plans - newser.com
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know - The Globe and Mail
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD - Investing.com
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.58%
4.09%
자본화:
|
볼륨(24시간):